New Preclinical Data Highlighting Eleven Biotherapeutics’ DeBouganin Program to be Presented at 2018 AACR Annual Meeting

On April 12, 2018 Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, reported that preclinical data from the company’s novel, next-generation ADC program using an innovative deBouganin cytotoxic protein payload will be presented during two poster sessions at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Eleven Biotherapeutics, APR 12, 2018, View Source [SID1234525276]). The meeting is taking place April 14-18, 2018 in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have uniquely designed our deBouganin payload to address tumor indications that can only be reached through systemic delivery. Our data show that deBouganin exhibits certain advantages over first-generation ADCs, which use more conventional small molecule cytotoxins, with respect to cell killing power, including the ability to kill cancer stem cells, circumvent multi-drug resistance and avoid cross-resistance mechanisms," said Gregory P. Adams, Ph.D., chief scientific officer of Eleven Biotherapeutics. "We are pleased to be presenting these promising data highlighting the potential activity and differentiation of our approach compared to first-generation ADCs."

DeBouganin is a proprietary de-immunized variant of bouganin, a ribosome inactivating protein that when internalized blocks protein synthesis, thereby leading to cell death. Eleven Biotherapeutics will present data from its VB6-845d program, a next-generation ADC comprised of a Fab fragment specific for the epithelial cell adhesion molecule (EpCAM) genetically linked to deBouganin via a furin protease sensitive peptide. Data being presented suggest that VB6-845d mediates tumor cell killing by an immunogenic cell death (ICD) pathway. The potential cross-priming effect initiated by VB6-845d-induced ICD suggests that VB6-845d in combination with immune checkpoint inhibitors may enhance their effectiveness in EpCAM-positive epithelial cancers.

Poster Title: VB6-845d Tumor Cell Killing Elicits Biologic Features of Immunogenic Cell Death
Date and Time:April 16, 2018 from 1:00 to 5:00 p.m. CT

In addition, in collaboration with Crescendo Biologics, the company will present data demonstrating that a fusion protein comprised of the company’s deBouganin payload and Crescendo’s Humabody are expressible as a soluble protein in E. coli supernatant. Crescendo’s Humabody products are a novel class of small, robust and potent protein therapeutics based on fully human VH domain building blocks. In vitro data support the potential of Humabody-deBouganin fusion constructs as anti-cancer therapeutics.

Poster Title: Engineering and Characterization of Anti-PSMA Humabody-DeBouganin Fusion Proteins

Date and Time:April 18, 2018 from 8:00 a.m. to 12:00 p.m. C